



Curriculum Vitae

** CV must be written in English*

Personal Information	
Title (i.e. Pf., Dr., etc.)	Dr
Name (First Name/ Middle Name /Last Name)	Peter Bossuyt
Degree (i.e. MD, MSc, PhD, etc.)	MD PhD
Country	Belgium
Affiliation	Imelda GI clinical research center
E-mail	Peter.bossuyt@imelda.be
	
Educational Background	
<p>Medical Doctor, 1996-2003, Magna cum Laude, Catholic University of Leuven, Belgium.</p> <p>Internal medicine, 2003-2006, Catholic University of Leuven, Belgium.</p> <p>Gastroenterology, 2006-2009; Catholic University of Leuven, Belgium.</p> <p>Advanced Therapeutic Endoscopy Fellow, 2009-2010, University of Amsterdam, The Netherlands</p> <p>Doctor of Philosophy (PhD), Catholic University of Leuven, Belgium. Title: Value of endoscopic scoring and imaging for the prognosis and follow up of IBD Promotor: Prof Séverine Vermeire September 28th 2021</p>	
Professional Career	
<p>Staff member Gastroenterology Department, Imelda General Hospital, Bonheiden Belgium 2010-present Department Director, Imelda GI clinical research centre, Bonheiden Belgium 2010-present Consulting staff member, University hospitals Leuven, Catholic University of Leuven, Belgium. 2010-2015 Scientific collaborator, Catholic University of Leuven, Belgium. 2021-present</p> <p>President Belgian IBD research and development group (BIRD) 2023-present Secretary Belgian IBD research and development group (BIRD) 2020-2023 Head of scientific committee Belgian IBD research and development group (BIRD) 2018-2020 National representative Belgium European Crohn and Colitis Organisation (ECCO) 2014-2017 Member ClinCom European Crohn and Colitis Organisation (ECCO) 2019-2023 Participant in Grade guidelines committee European Crohn and Colitis Organisation (ECCO) 2018-2019 Board member Belgian society of gastrointestinal endoscopy (BSGIE) Coordinator quality project IBD Flemisch Hospital Network Catholic University of Leuven.</p>	
Research Field	
<p>Research focuses on clinical trials in IBD and the definitions of endoscopic and imaging targets in IBD. Application of e-health tools and AI in IBD. Strategy trials in IBD.</p>	
Main Scientific Publications	
<p>1. Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, Ferrante M, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. <u>Gut</u>. 2020 Oct;69(10):1778-1786.</p>	



2. **Bossuyt P**, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Parient B, Filippi J, Baert F, D'haens G, Laharie D, Peyrin-Biroulet L, Vermeire S. Infliximab exposure associates with radiologic evidence of healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2021 May;19(5):947-954.
3. **Bossuyt P**, De Hertogh G, Eelbode T, Vermeire S, Bisschops R. Computer aided diagnosis with monochromatic light endoscopy for scoring histological remission in ulcerative colitis. Gastroenterology. 2021 Jan;160(1):23-25.
4. **Bossuyt P**, Pouillon L, Claeys S, D'Haens S, Hoefkens E, Strubbe B, Marichal D, Peeters H. Ultra-proactive therapeutic drug monitoring of infliximab based on point-of-care-testing in inflammatory bowel disease: results of a pragmatic trial. J Crohns Colitis. 2022 Feb 23;16(2):199-206.
5. Colombel JF, Panaccione R, **Bossuyt P**, Lukas M, Baert F, Vađásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018; 390(10114): 2779-2789.
6. Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin B, Colombel JF, Laine L, Danese S; True North Study Group (**Bossuyt P** among investigators). Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 Sep 30;385(14):1280-1291.
7. D'Haens G, Panaccione R, Baert F, **Bossuyt P**, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015-2030.
8. Ferrante M, Panaccione R, Baert F, **Bossuyt P**, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 May 28;399(10340):2031-2046.
9. Peyrin-Biroulet L, Chapman JC, Colombel J-F, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese D, Lindsay J, **Bossuyt P**, Siegmund B, Irving P, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan R, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M, for the SEQUENCE Study Group. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. N Engl J Med. 2024 accepted in press
10. Louis E, Schreiber S, Panaccione R, **Bossuyt P**, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024 Jul 22:e2412414. doi: 10.1001/jama.2024.12414.

- Please note that the above information will be used for the introduction of speakers for the IMKASID 2025 website and announcements. Also, it will be provided to the session chairpersons before your lecture.

- Please complete this form (no more than 2 pages) and return it to the IMKASID 2025 secretariat by email, info@imkasid.kr.